Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Impotence in patients treated with clofibrate.

J Schneider, H Kaffarnik

    Atherosclerosis
    |May 1, 1975
    PubMed
    Summary

    Clofibrate treatment for hyperlipoproteinemia may cause impotence in some patients. Symptoms improved after stopping the drug, but recurred upon re-administration in one case.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease.

    Atherosclerosis·1999
    Same author

    [Alcohol, lipid metabolism and coronary heart disease].

    Herz·1996
    Same author

    Multicenter comparison of micronized fenofibrate and simvastatin in patients with primary type IIA or IIB hyperlipoproteinemia.

    Journal of cardiovascular pharmacology·1996
    Same author

    [Oral contraceptive-induced pancreatitis in the hyperchylomicronemia syndrome].

    Deutsche medizinische Wochenschrift (1946)·1995
    Same author

    Influence of somatostatin to biochemical parameters in patients with primary hyperparathyroidism.

    Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association·1995
    Same author

    [Adrenomyeloneuropathy. A frequent cause of Addison's disease].

    Deutsche medizinische Wochenschrift (1946)·1994

    Area of Science:

    • Cardiology
    • Endocrinology
    • Pharmacology

    Background:

    • Type IV hyperlipoproteinemia is a lipid disorder requiring management.
    • Clofibrate is a medication used to treat hyperlipoproteinemia.
    • Cardiovascular risk factors, including hyperlipidemia and prior myocardial infarction, are significant.

    Purpose of the Study:

    • To investigate the potential link between clofibrate therapy and impotence.
    • To assess the reversibility of impotence after clofibrate discontinuation.

    Main Methods:

    • Observational case series involving three patients with Type IV hyperlipoproteinemia.
    • Monitoring of sexual function in patients undergoing clofibrate treatment.
    • Interruption and re-initiation of clofibrate therapy to evaluate symptom changes.

    Main Results:

    • Three patients developed impotence within one year of starting clofibrate.
    • Two patients experienced symptom improvement within 3-4 weeks of drug cessation.
    • Impotence recurred in one patient upon resuming clofibrate therapy.

    Conclusions:

    • Clofibrate may be associated with the development of impotence in patients with Type IV hyperlipoproteinemia.
    • The observed impotence appears to be reversible upon discontinuation of clofibrate.
    • Further investigation into the mechanism and prevalence of this side effect is warranted.

    Related Experiment Videos